<DOC>
	<DOCNO>NCT01357330</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerate dose ( ) ( MTD ) recommend Phase 2 dose ( ) ( RP2D ) SAR245408 MSC1936369B combine adult subject locally advance metastatic solid tumor . Secondary Objective : - To characterize safety tolerability SAR245408 MSC1936369B combination therapy administer orally adult patient locally advance metastatic solid tumor - To evaluate pharmacokinetic ( PK ) profile SAR245408 MSC1936369B use combination - To evaluate pharmacodynamic ( PD ) effect SAR245408/MSC1936369B combination assess target pathway inhibition</brief_summary>
	<brief_title>Oral SAR245408 ( XL147 ) Oral MSC1936369B Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>The duration study include period screen maximum 28 day , pretreatment evaluation period 5 day , on-treatment period , follow minimum 30-day follow-up last study drug administration . The patient may continue study treatment disease progression , unacceptable toxicity , consent withdrawal . The study 2 part : - Part one - Dose Escalation - Part Two - Expansion . At defined maximum tolerated dos ( MTD ( ) , additional patient enrol collect safety , Pharmacokinetic , Pharmacodynamic data</detailed_description>
	<criteria>Inclusion criterion : Patient advance solid tumor approve curative therapy : advanced solid tumor diagnose alteration 1 gene PI3K , mitogenactivated protein kinase ( MAPK ) pathways and/or histologically cytologically confirm diagnosis 1 follow solid tumor : pancreatic , thyroid , colorectal , nonsmall cell lung , endometrial , renal , breast , ovarian carcinoma melanoma Exclusion criterion : The patient previously treat PI3K inhibitor Mitogenactivated protein extracellular signalregulated kinase ( MEK ) inhibitor The patient receive : Chemotherapy , immunotherapy , hormonal therapy , biologic therapy , anticancer therapy within 28 day 5 half life noncytotoxics ( whichever short ) Day 1 trial drug treatment ( 6 week nitrosureas mitomycin C ) Any investigational agent within 28 day Day 1 trial drug treatment The patient currently receive anticoagulation therapy therapeutic dos warfarin ( lowdose warfarin â‰¤1 mg/day , heparin , lowmolecular weight heparin permit ) History central nervous system metastases The patient congestive heart failure , unstable angina , myocardial infarction , cardiac conduction abnormality pacemaker stroke within 3 month enter study . The patient retinal degenerative disease ( hereditary retinal degeneration agerelated macular degeneration ) , history uveitis , history retinal vein occlusion , medically relevant abnormality identify screen ophthalmologic examination . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>locally advanced metastatic</keyword>
</DOC>